Ardelyx, Inc. (ARDX)

Last Price:  

Company Description

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $7.57M
Net Income (Most Recent Fiscal Year) $-94.31M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 10.55
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.07
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -1009.29%
Net Margin (Trailing 12 Months) -1009.33%
Return on Equity (Trailing 12 Months) -99.11%
Return on Assets (Trailing 12 Months) -61.48%
Current Ratio (Most Recent Fiscal Quarter) 3.23
Quick Ratio (Most Recent Fiscal Quarter) 3.23
Debt to Common Equity (Most Recent Fiscal Quarter) 0.13
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $1.40
Earnings per Share (Most Recent Fiscal Quarter) $-0.45
Earnings per Share (Most Recent Fiscal Year) $-1.05
Diluted Earnings per Share (Trailing 12 Months) $-1.31
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 103.12M
Free Float 96.98M
Market Capitalization $130.96M
Average Volume (Last 20 Days) 3.55M
Beta (Past 60 Months) 1.81
Percentage Held By Insiders (Latest Annual Proxy Report) 5.95%
Percentage Held By Institutions (Latest 13F Reports) 82.04%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%